Optimal management of cancer treatment-induced bone loss: Considerations for elderly patients

Drugs and Aging

Volumn 28, Issue 11, 2011, Pages 867-883

  Tipples, Karen ^a   Robinson, Anne ^a  

^a BASILDON HOSPITAL   (United Kingdom)

Author keywords

Alendronic acid; Bisphosphonates; Bone; Breast cancer; Cancer; Clodronic acid; Elderly; Ibandronic acid; Multiple myeloma; Osteoporosis; Pamidronic acid; Prostate cancer; Risedronic acid; Tamoxifen; Zoledronic acid

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; LETROZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CANCER THERAPY; CARDIOTOXICITY; DIET; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FRACTURE; HUMAN; JAW OSTEONECROSIS; LIFESTYLE; MULTIPLE MYELOMA; NEPHROTOXICITY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SMOKING HABIT; TOXICITY TESTING;

AGED; ANTINEOPLASTIC AGENTS; BONE DISEASES; FRACTURES, BONE; HUMANS; NEOPLASMS;

EID: 80755159595     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11595820-000000000-00000     Document Type: Review

References (110)

1. Tyczynski JE, Plesko I, Aareleid A, et al. Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly. Int J Cancer 2004; 112: 1056-64 (Pubitemid 39507014)
2. Sweeney C, Blair CK, Anderson KE, et al. Risk factors for breast cancer in elderly women. Am J Epidemiol 2004; 160: 868-75 (Pubitemid 39434771)
3. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000; 18: 1709-17 (Pubitemid 30220549)
4. Prostate cancer-UK incidence statistics. London: Cancer Research UK, 2011 [online]. Available from URL: http://info.cancerresearchuk.org/cancerstats/ types/prostate/inci dence/[Accessed 2011 Aug 2]
5. Brenner H, Gondos A, Pulte D. Expected long-term sur-vival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009; 94: 270-5
6. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-20
7. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004 Apr 15; 350 (16): 1655-64
8. Kobayashi Y, Udagawa N, Takahashi N. Action of RANKL and OPG for osteoclastogenesis. Crit Rev Eukaryot Gene Expr 2009; 19 (1): 61-72
9. Hadji P, Ziller M, Albert US, et al. Assessment of fracture risk in women with breast cancer using current vs emerging guidelines. Br J Cancer 2010; 102 (4): 645-50
10. Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367: 2010-18 (Pubitemid 43867702)
11. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005; 16: 1330-8 (Pubitemid 41532085)
12. Serpa Neto A, Tobias-Machado M, Esteves MA, et al. A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma [abstract]. BMC Urol 2010 May 19; 10: 9
13. Milani M, Jha G, Potter D. Anastrazole use in early stage breast cancer of post-menopausal women. Clin Med Ther 2009; 1: 141-56
14. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmeno-pausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619-29 (Pubitemid 46224240)
15. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporosis Int 2007; 18: 1033-46 (Pubitemid 47020000)
16. Eastell R, Lambert H. Strategies for skeletal health in the elderly. Proc Nutr Soc 2002; 61 (2): 173-80 (Pubitemid 34665791)
17. Maillefert JF, Sibilia J, Michel F, et al. Bone mineral den-sity in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999 Apr; 161 (4): 1219-22 (Pubitemid 29426121)
18. Janni W, Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 2010; 36: 249-61
19. Gonnelli S, Petrioli R. Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. Clin Interv Aging 2008; 3: 647-57
20. Sainsbury R, on behalf of the ATAC Trialists Group. Anastrozole shows greater carryover effects compared with tamoxifen and resolution of fracture risk post treatment: data from ATAC at 100 months' median follow up [poster no. 263]. European Breast Cancer Conference; 2008 Apr 15-19; Berlin
21. Coates A, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG1-98. J Clin Oncol 2007; 25: 486-92 (Pubitemid 350002953)
22. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years of tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007; 369: 559-70
23. Goss P. Update on the MA.17 extended adjuvant trial. Best Pract Res Clin Endocrinol Metab 2006; 20 Suppl. 1: S5-13
24. Grey AS, Stapleton JP, Evans MC, et al. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995; 99: 636-41 (Pubitemid 26006445)
25. Resch A, Biber E, Seifert M, et al. Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer. Acta Oncol 1998; 37: 661-4 (Pubitemid 29066817)
26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717
27. Lee RJ, Savior PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer 2010; 8: 29-30
28. Shaninian VB, Kuo Y-F, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64 (Pubitemid 40096612)
29. Horwich A, Parker C, Bangma C, et al., ESMO Guidelines Working Group. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 Suppl. 5: v129-33
30. Mittan D, Lee S, Miller E, et al. Bone loss following hy-pogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002; 87: 3656-61 (Pubitemid 34879508)
31. Kiratli BJ, Srinivas S, Perkash I, et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001 Jan; 57 (1): 127-32 (Pubitemid 32065833)
32. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal frac-tures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-7
33. Alibhai SM, Duong-Hua M, Cheung AM, et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19.079 men. J Urol 2010; 184 (3): 918-23
34. Terpos E, Sezer O, Croucher PI, et al. The use of bisphos-phonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009 Aug; 20 (8): 1303-17
35. Coleman RE. Skeletal complications of malignancy. Can-cer 1997; 80: 1588-94 (Pubitemid 27444031)
36. Croucher PI, Apperley JF. Bone disease in multiple mye-loma. Br J Haematol 1998; 103: 902-10
37. Tuck S. Glucocorticoid-induced osteoporosis. Osteoporos Rev 2009; 17 (4): 1-6
38. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004 Apr; 145(4): 1835-41 (Pubitemid 38402392)
39. Van Staa TP. The pathogenesis, epidemiology and man-agement of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006; 79: 129-37 (Pubitemid 44440440)
40. Licata A. Bone density vs bone quality: what's a clinician to do? Cleve Clin J Med 2009; 76: 331-6
41. Siris ES, Brenneman SK, Miller PD, et al. Predictive value of low BMD for 1 year fracture outcomes is similar for postmenopausal women aged 50-64 and 65 and older: results from National Osteoporosis Risk Assessment (NORA). J Bone Miner Res 2004; 19: 1215-20 (Pubitemid 41094361)
42. FRAX®: WHO fracture risk assessment tool. Sheffield: WHO Collaborating Centre for Metabolic Bone Diseases [online]. Available from URL: http://www.shef.ac.uk/FRAX [Accessed 2011 Sep 22]
43. Cremers S, Garnero P. Biochemical markers of bone turn-over in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 2006; 66 (16): 2031-58 (Pubitemid 46372356)
44. Kuroda I, Ueno M. Biochemical markers of bone turnover: new aspect. Bone metabolic markers in prostatic carcinoma. Clin Calcium 2009 Aug; 19 (8): 1170-7
45. Hillner B, Ingle J, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphos-phonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-57 (Pubitemid 46606220)
46. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treatment Reviews 2008; 34 Suppl. 1: S3-18
47. Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer: a consensus paper of the Belgian Bone Club. Osteoporos Int 2007 Nov; 18 (11): 1439-50 (Pubitemid 47512686)
48. Ross RW, Small EJ. Osteoporosis in men treated with an-drogen deprivation therapy for prostate cancer. J Urol 2002; 167: 1952-6 (Pubitemid 34309635)
49. British Committee for Standards in Haematology in con-junction with the UK Myeloma Forum (UKMF). Guidelines on the diagnosis and management of multiple myeloma. London: British Society for Haematology, 2010 [online]. Available from URL: http://www.bcshguideli nes.com/documents/MYELOMA-Mngmt-GUIDELINE- REVISION-Sept-2010.pdf [Accessed 2011 Sep 22]
50. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003; 5: 65-74
51. Fournier PG, Stresing V, Ebetino FH, et al. How do bisphosphonates inhibit bone metastasis in vivo? Neo-plasia 2010; 12 (7): 571-8
52. Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach and colorectum: case control analysis within a UK primary care cohort. BMJ 2010; 341: c4444
53. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676-9
54. Cardwell CR, Abnet CC, Cantwell MM, et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010; 304: 657-63
55. Information for healthcare professionals: bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Di-dronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zo-meta). Silver Spring (MD): US FDA. 2008 [online]. Available from URL: http://www.fda.gov/Drugs/Drug Safety/ PostmarketDrugSafetyInformationforPatientsand Providers/ucm124165.htm [Accessed 2011 Sep 20]
56. Black DM, Kelly MP, Genant HK, et al. Bisphophonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362: 1761-71
57. Wilkinson GS, Baillargeon J, Kuo YF, et al. Atrial fi-brillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol 2010 Nov 20; 28 (33): 4898-905
58. Cheung A, Seeman E. Teriparatide therapy for alen-dronate-associated osteonecrosis of the jaw. N Engl J Med 2010 Dec 16; 363 (25): 2473-4
59. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphos-phonate therapy and fracture rate in osteoporotic women: relationship to vertebral and non vertebral fractures from 2 US databases. Mayo Clin Proc 2006; 81: 1013-22 (Pubitemid 44175011)
60. Saarto T, Vehmanen L, Blomqvist C, et al. Ten year follow up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early stage breast cancer. J Clin Oncol 2008; 26: 4289-95
61. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology 2006; 20 (9): 1029-39 (Pubitemid 46947932)
62. Confavreux CB, Fontana A, Guastalla JP, et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole: prevention with bisphosphonates. Bone 2007; 41: 346-52 (Pubitemid 47199159)
63. Greenspan SL, Brufsky A, Lembersky BC, et al. Rise-dronate prevents bone loss in breast cancer survivors: a 2 year randomised, double blind, placebo controlled clinical trial. J Clin Oncol 2008; 26: 2644-52
64. Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase-inhibitor bone loss using risedronate: the SABRE trial. J Clin Oncol 2010; 28 (6): 967-75
65. Clinical Care Options. Multidisciplinary approaches and treatment considerations for managing skeletal integrity in cancer patients [online]. Available from URL: http://www.clinicaloptions.com/Oncology/Treatment%20Updates/ Bone%20Complications.aspx [Accessed 2011 Feb 18]
66. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral iban-dronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14: 6336-42
67. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42 446, a new potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-51 (Pubitemid 24130477)
68. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004; 11 (2): 207-24 (Pubitemid 38832826)
69. Huas D, Debiais F, Blotman F, et al. Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. BMC Womens Health 2010; 10: 6
70. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zole-dronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61 (Pubitemid 34815869)
71. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010 Nov; 21 (11): 2188-94
72. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zole-dronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009 May; 9 (2): 77-85
73. Logman F, Heeg B, Botteman MF, et al. Cost-effectiveness of zoledronic acid in the prevention of fractures in post-menopausal women with early breast cancer receiving aromatase inhibitor: application to the United Kingdom [abstract no. 1146]. 14th European Cancer Conference (ECCO); 2007 Sep 23-27; Barcelona
74. Greenspan SL, Nelson JB, Trump DL. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146 (6): 416-24 (Pubitemid 351650576)
75. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25 (9): 1038-42 (Pubitemid 46596753)
76. Smith MR, Eastham J, Gleason DM. Randomized con-trolled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003 Jun; 169 (6): 2008-12 (Pubitemid 36576705)
77. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-51
78. Djulbegovic B, Wheatley K, Ross J, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002; (3): CD003188
79. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991 Aug; 9 (8): 1397-402
80. Berenson JR, Lichtenstein A, Porter L, et al. Long term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16 (2): 593-602 (Pubitemid 28135605)
81. Morgan G, Davies F, Gregory W, et al. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): results of the Medical Research Council (MRC) Myeloma IX study [abstract no. 8021]. J Clin Oncol 2010; 28 Suppl.: 15s [online]. Available from URL: http://www.asco.org/AS COv2/Meetings/Abstracts?&vmview=abst-detail- view& confID=74&abstractID=54136 [Accessed 2011 Sep 22]
82. Neville-Webbe HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 2010; 46: 1211-22
83. Ellis GK, Bone HG, Chlebowski R, et al. Effect of denosu-mabon bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 2009 Nov; 118 (1): 81-7
84. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zolendronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2001; 377: 813-22
85. Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009; 182 (6): 2670-5
86. Body JJ, Facon T, Coleman RE, et al. A study of the biolo-gical activator of nuclear factor Kappa B ligand inhibitor denosumab in patients with multiple myeloma or bone me-tastases from breast cancer. Clin Cancer Res 2006; 12: 1221-8 (Pubitemid 43342512)
87. Vij R, Horvath N, Spencer A, et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol 2009 Oct; 84 (10): 650-6
88. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-71
89. Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2008; 2: 2197-203
90. Howe TE, Shea B, Dawson LT. Exercise for preventing and treating osteoporosis in postmenopausal women. Co-chrane Database Syst Rev 2001; 7: CD000333
91. Glucocorticoid-induced osteoporosis: a concise guide to prevention and treatment. London: Royal College of Physicians. 2002 [online]. Available from URL: http://bookshop.rcplondon.ac.uk/contents/pub89-64206b70-b147-4976-9ee1- bf4948458468.pdf [Accessed 2011 Aug 11]
92. Peppone LJ, Mustian KM, Janelsins MC. Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial. Clin Breast Cancer 2010; 10: 224-9
93. Lindsey AM, Gross F, Twiss J. Postmenopausal survivors of breast cancer at risk for osteoporosis: nutritional intake and body size. Cancer Nurs 2002; 25: 50-6 (Pubitemid 34101407)
94. Ito T, Jensen RT. Associations of long-term proton pump inhibitor therapy with bone fractures: effects on absorption of calcium, vitamin B12, iron and magnesium. Curr Gastroenterol Rep 2010; 12: 448-57
95. Taylor EN, Curhan GC. Demographic, dietary and urinary factors and 24 h urinary calcium excretion. Clin J Am Soc Nephrol 2009; 4: 1980-7
96. Heller HJ, Greer LG, Haynes SD, et al. Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women. J Clin Pharmacol 2000; 40: 1237-12
97. The National Osteoporosis Foundation. Guidelines on calcium supplementation [online]. Available from URL: http://www.nof.org/ aboutosteoporosis/prevention/calcium [Accessed 2011 Aug 2]
98. Chlebowski RT, Taqawa T. Early breast and prostate cancer and clinical outcomes (fracture). Oncology (Will-iston Park) 2009; 23 (14 Suppl. 5): 16-20
99. Corcoran ME. Poly-pharmacy in the older patient with cancer. Cancer Control 1997; 4: 419-28
100. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitali-zations of the elderly. Arch Intern Med 1990; 150: 841-5 (Pubitemid 20122061)
101. Hogan DB, Ebly EM, Fung TS. Disease, disability, and age in cognitively intact seniors: results from the Canadian study of health and aging. J Gerontol 1999; 54A: M77-82 (Pubitemid 29093846)
102. International Osteoporosis Foundation. The adherence gap: why osteoporosis patients don't continue with treatment. Geneva: IOF, 2005
103. Barton J, Worcester G, Ryan PJ. Long term treatment adherence from a fracture liaison clinic [letter]. Osteo-poros Int 2003; 14 Suppl. 4: S12
104. Fraser M, McLellan AR. Empowering patients with osteoporosis: insights from a patient education meeting [letter]. Osteoporos Int 2003; 16 Suppl. 4: S33
105. Grahn Kronhed AC, Blomberg C, Karlsson N, et al. Impact of a community-based osteoporosis and fall prevention program on fracture incidence. Osteoporos Int 2005; 16 (6): 700-6 (Pubitemid 40897468)
106. Black DM, Reid I, Cauley J, et al. The effect of three versus six years of zoledronic acid treatment in osteoporosis: a randomized extension of the HORIZON pivotal fracture-prevention study [abstract no. 1070]. 2010 Annual Meeting of the American Society for Bone and Mineral Research; 2010 Oct 15-19; Toronto (ON)
107. Papapoulos S, Bone H, Brandi M, et al. Four years of de-nosumab exposure in women with PMO: results from the first year extension of the FREEDOM trial [abstract no. 1025]. 2010 Annual Meeting of the American Society for Bone and Mineral Research; 2010 Oct 15-19; Toronto (ON)
108. Cocks K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007; 43: 1670-8 (Pubitemid 47042371)
109. Vogel CL, Yanagihara RH, Wood AJ, et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 2004; 9: 687-95 (Pubitemid 39546408)
110. Curry LC, Hogstel MO, Davis GC. Functional status for older women following hip fracture. J Adv Nur 2003; 42: 347-54 (Pubitemid 37255912)